For the first time in the history of the human race, CRISPR-based genome editing has enabled us to safely and effectively change our DNA, the code of life. While tremendous progress has been made in translating this new technology into medicines, if we continue to take a traditional approach to drug development, we will never realize the full potential of this breakthrough to treat patients suffering from rare genetic diseases. Fortunately, by leveraging the modularity of our gene editing platforms, we can greatly streamline drug development and ensure that no patient is denied access to a lifesaving therapy simply because their disease is considered “too rare.” Dr. Sean Burns is Vice President of the Disease Biology team at Intellia Therapeutics, where he leads the company's efforts to identify novel in vivo applications of CRISPR genome editing to treat genetic disease. In addition, Sean is a practicing endocrinologist affiliated with Massachusetts General Hospital and Nantucket Cottage Hospital. Before joining Intellia, Sean was a physician-scientist at Mass General and the Broad Institute of Harvard and MIT. He received his B.S. in Electrical Engineering from Cornell University, and his M.D. with Honors from the New York University School of Medicine. He is a proud member of the Milton Academy Class of 1994. This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at www.ted.com/tedx
12 дек 2023
